RATIONALE: Exacerbations are important and heterogeneous events in the natural history of chronic obstructive pulmonary disease (COPD). OBJECTIVES: To examine the consequences of prolonged exacerbation recovery in patients with COPD. METHODS: A cohort of 384 patients with COPD (FEV1 % predicted 45.8 [SD, 16.6] and a median exacerbation rate of 2.13 per year [interquartile range, 1.0-3.2]) were followed for 1,039 days (interquartile range, 660-1,814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent spirometry every 3 months, and completed the St. George's Respiratory Questionnaire annually. Exacerbations were diagnosed as 2 consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding 2 consecutive symptom-free days and recovery in PEF as return to preexacerbation levels. MEASUREMENTS AND MAIN RESULTS: A total of 351 patients had one or more exacerbations. Patients with a longer symptom duration (mean, 14.5 d) had a worse St. George's Respiratory Questionnaire total score (0.2 units per 1 day; P = 0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (hazard ratio, 1.004; P = 0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these nonrecovered exacerbations showed a 10.8 ml/yr (P < 0.001) faster decline in FEV1. CONCLUSIONS: Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1.
RATIONALE: Exacerbations are important and heterogeneous events in the natural history of chronic obstructive pulmonary disease (COPD). OBJECTIVES: To examine the consequences of prolonged exacerbation recovery in patients with COPD. METHODS: A cohort of 384 patients with COPD (FEV1 % predicted 45.8 [SD, 16.6] and a median exacerbation rate of 2.13 per year [interquartile range, 1.0-3.2]) were followed for 1,039 days (interquartile range, 660-1,814) between October 1995 and January 2013. Patients recorded daily worsening of respiratory symptoms and peak expiratory flow (PEF), and when stable underwent spirometry every 3 months, and completed the St. George's Respiratory Questionnaire annually. Exacerbations were diagnosed as 2 consecutive days with one major symptom plus another respiratory symptom. Exacerbation duration was defined as the time from onset to the day preceding 2 consecutive symptom-free days and recovery in PEF as return to preexacerbation levels. MEASUREMENTS AND MAIN RESULTS: A total of 351 patients had one or more exacerbations. Patients with a longer symptom duration (mean, 14.5 d) had a worse St. George's Respiratory Questionnaire total score (0.2 units per 1 day; P = 0.040). A longer symptomatic duration was associated with a shorter interval between exacerbation recovery and onset of the next exacerbation (hazard ratio, 1.004; P = 0.013). For 257 (7.3%) exacerbations, PEF did not recover within 99 days. These exacerbations were associated with symptoms of a viral infection (cold and sore throat). Patients with these nonrecovered exacerbations showed a 10.8 ml/yr (P < 0.001) faster decline in FEV1. CONCLUSIONS: Prolonged exacerbation symptomatic duration is associated with poorer health status and a greater risk of a new event. Exacerbations where lung function does not recover are associated with symptoms of viral infections and accelerated decline in FEV1.
Authors: Davinder S Garcha; Sarah J Thurston; Anant R C Patel; Alexander J Mackay; James J P Goldring; Gavin C Donaldson; Timothy D McHugh; Jadwiga A Wedzicha Journal: Thorax Date: 2012-08-03 Impact factor: 9.139
Authors: Patrick Mallia; Joseph Footitt; Rosa Sotero; Annette Jepson; Marco Contoli; Maria-Belen Trujillo-Torralbo; Tatiana Kebadze; Julia Aniscenko; Gregory Oleszkiewicz; Katrina Gray; Simon D Message; Kazuhiro Ito; Peter J Barnes; Ian M Adcock; Alberto Papi; Luminita A Stanciu; Sarah L Elkin; Onn M Kon; Malcolm Johnson; Sebastian L Johnston Journal: Am J Respir Crit Care Med Date: 2012-09-28 Impact factor: 21.405
Authors: Sîobhán N George; Davinder S Garcha; Alexander J Mackay; Anant R C Patel; Richa Singh; Raymond J Sapsford; Gavin C Donaldson; Jadwiga A Wedzicha Journal: Eur Respir J Date: 2014-03-13 Impact factor: 16.671
Authors: Gavin C Donaldson; Hanna Müllerova; Nicholas Locantore; John R Hurst; Peter M A Calverley; Jorgen Vestbo; Antonio Anzueto; Jadwiga A Wedzicha Journal: Respir Res Date: 2013-07-30
Authors: Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin Journal: Chronic Obstr Pulm Dis Date: 2016-11-15
Authors: Mark T Dransfield; Ken M Kunisaki; Matthew J Strand; Antonio Anzueto; Surya P Bhatt; Russell P Bowler; Gerard J Criner; Jeffrey L Curtis; Nicola A Hanania; Hrudaya Nath; Nirupama Putcha; Sarah E Roark; Emily S Wan; George R Washko; J Michael Wells; Christine H Wendt; Barry J Make Journal: Am J Respir Crit Care Med Date: 2017-02-01 Impact factor: 21.405
Authors: S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe Journal: JCI Insight Date: 2016-09-22
Authors: Guang-Shing Cheng; Barry Storer; Jason W Chien; Madan Jagasia; Jesse J Hubbard; Linda Burns; Vincent T Ho; Joseph Pidala; Jeanne Palmer; Laura Johnston; Sebastian Mayer; Kristina Crothers; Iskra Pusic; Stephanie J Lee; Kirsten M Williams Journal: Ann Am Thorac Soc Date: 2016-11
Authors: Andy I Ritchie; Jonathon R Baker; Trisha M Parekh; James P Allinson; Surya P Bhatt; Louise E Donnelly; Gavin C Donaldson Journal: Am J Respir Crit Care Med Date: 2021-07-01 Impact factor: 21.405